<SEC-DOCUMENT>0001654954-17-005710.txt : 20170619
<SEC-HEADER>0001654954-17-005710.hdr.sgml : 20170619
<ACCEPTANCE-DATETIME>20170619181625
ACCESSION NUMBER:		0001654954-17-005710
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20170619
FILED AS OF DATE:		20170619
DATE AS OF CHANGE:		20170619

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TG THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001001316
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				363898269
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		2 GANSEVOORT STREET, 9TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10014
		BUSINESS PHONE:		(212) 554-4484

	MAIL ADDRESS:	
		STREET 1:		2 GANSEVOORT STREET, 9TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10014

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MANHATTAN PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20030310

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ATLANTIC TECHNOLOGY VENTURES INC
		DATE OF NAME CHANGE:	20000330

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ATLANTIC PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19960703

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			WEISS MICHAEL S
		CENTRAL INDEX KEY:			0001038977

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32639
		FILM NUMBER:		17919470

	MAIL ADDRESS:	
		STREET 1:		750 LEXINGTON AVE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>section16.xml
<DESCRIPTION>FORM-4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2017-06-19</periodOfReport>

    <issuer>
        <issuerCik>0001001316</issuerCik>
        <issuerName>TG THERAPEUTICS, INC.</issuerName>
        <issuerTradingSymbol>TGTX</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001038977</rptOwnerCik>
            <rptOwnerName>WEISS MICHAEL S</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>2 GANSEVOORT ST, 9TH FLOOR</rptOwnerStreet1>
            <rptOwnerStreet2></rptOwnerStreet2>
            <rptOwnerCity>NEW YORK</rptOwnerCity>
            <rptOwnerState>NY</rptOwnerState>
            <rptOwnerZipCode>10014</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>false</isDirector>
            <isOfficer>true</isOfficer>
            <isTenPercentOwner>false</isTenPercentOwner>
            <isOther>false</isOther>
            <officerTitle>CEO and President</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>COMMON STOCK</value>
                <footnoteId id="F1"/>
            </securityTitle>
            <transactionDate>
                <value>2017-06-19</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>G</transactionCode>
                <equitySwapInvolved>false</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>350000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0.00</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>9795917</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>COMMON STOCK (RESTRICTED)</value>
            </securityTitle>
            <transactionDate>
                <value>2017-06-19</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>false</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>834877</value>
                    <footnoteId id="F2"/>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0.00</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>10630794</value>
                    <footnoteId id="F3"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>See Note 4</value>
                    <footnoteId id="F4"/>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">Reflects the transfer of 350,000 shares of TG Therapeutics stock to the Weiss Family and Descendants Trust.</footnote>
        <footnote id="F2">Reflects an annual grant of restricted stock pursuant to the Strategic Advisory Agreement with Caribe BioAdvisors, LLC, pursuant to which Mr. Weiss provides the services of Chairman of the Board and Executive Chairman. The restricted shares will vest on the date that the Company's Market Capitalization is $100 million greater than the Market Capitalization on the date of grant; provided however, if the market capitalization threshold is met prior to June 30, 2018 then the shares shall vest on June 30, 2018.</footnote>
        <footnote id="F3">Included in Mr. Weiss' beneficial ownership are 4,910,010 shares of Common Stock issued to Opus Point Partners, LLC, of which Mr. Weiss is a co-founder, managing partner, and principal and beneficially owns a 50% interest.</footnote>
        <footnote id="F4">The shares are held by Caribe BioAdvisors, LLC, of which Mr. Weiss is the sole member.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Michael Weiss</signatureName>
        <signatureDate>2017-06-19</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
